Clinical Trial Goal
To find out:
- The highest dose of tazemetostat that’s safe to give with venetoclax
- If the combination of tazemetostat and venetoclax is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have NHL that has relapsed or is refractory. Some examples include:
- Anaplastic large cell lymphoma (ALCL)
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Cutaneous T-cell lymphoma (CTCL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma (MCL)
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- T-cell lymphoma
- Waldenström macroglobulinemia
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with tazemetostat or venetoclax
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Tazemetostat is a small molecule inhibitor that blocks EZH2 in certain cells.
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Venetoclax is a small molecule inhibitor that blocks BCL2 in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Tazemetostat – A pill that you take by mouth 2 times each day
- Venetoclax – A pill that you take by mouth 1 time each day
You may continue treatment for up to 2 years. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. Using them in this way to treat NHL that has relapsed or is refractory is new and unproven.
Contacts
Tejasvi Kaur Sahni, 646-962-8189, tks4001@med.cornell.edu
Brittany Hobbie, brh4008@med.cornell.edu
Locations
Weill Cornell Medicine/NewYork-Presberteryian HospitalRECRUITING
New York, New York
Contacts:
- Tejasvi Kaur Sahni, 646-962-9337, tks4001@med.cornell.edu
- Brittany Hobbie, brh4008@med.cornell.edu
Sponsors
collaborator: Genentech, Inc., collaborator: Epizyme, Inc., lead: Weill Medical College of Cornell University
